Anti-Hu CD49d Purified

Anti-Hu CD49d Purified
Regulatory status
RUO
Antigen
CD49d
Clone
9F10
Format
Purified
Reactivity
Sheep, Cat, Horse, Dog, Cow, Non-human primates, Human
Application
FC (QC tested), IHC(F)
Variant
0.1 mg
11-171-C100
In stock

0.025 mg
11-171-C025
Out of stock
Variant
0.1 mg
11-261-C100
In stock

0.1 mg
11-261-C100
In stock
Product details
References
Isotype
Mouse IgG1 kappa
Specificity
The mouse monoclonal antibody 9F10 recognizes CD49d (alpha 4 integrin), a 145-180 kDa type I transmembrane glycoprotein expressed on B and T cells, monocytes, eosinophils, basophils, NK cells, and dendritic cells, but not platelets.
Workshop
HLDA V: WS Code S215
Application
FC (QC tested), IHC(F)
Reactivity
Sheep, Cat, Horse, Dog, Cow, Non-human primates, Human
Other names
ITGA4, Integrin alpha-4, VLA-4 alpha, VLA4 alpha
Concentration
1 mg/ml
Preparation
Purified by protein-A affinity chromatography
Formulation
Phosphate buffered saline (PBS) solution with 15 mM sodium azide
Storage and handling
Store at 2-8°C. Do not freeze. Do not use after expiration date stamped on vial label.
Exbio licence note
Unless indicated otherwise, all products are For Research Use Only and not for diagnostic use. In vivo diagnostic or therapeutic applications are strictly forbidden. Products shall not be used for resale or transfer to third parties either as a stand-alone product or as a manufacture component of another product without written consent of EXBIO Praha, a.s. EXBIO Praha, a.s. will not be held responsible for patent infringement or any other violations of intellectual property rights that may occur with the use of the products. Orders for all products are accepted subject to the Term and Conditions available at www.exbio.cz. EXBIO, EXBIO Logo, and all other trademarks are property of EXBIO Praha, a.s. © 2019 EXBIO Praha, a.s. All rights reserved.

Product specific references:

Stenner MP, Waschbisch A, Buck D, Doerck S, Einsele H, Toyka KV, Wiendl H: Effects of natalizumab treatment on Foxp3+ T regulatory cells. PLoS One. 2008 Oct 6;3(10):e3319.
PubMed
Chigaev A, Waller A, Amit O, Halip L, Bologa CG, Sklar LA: Real-time analysis of conformation-sensitive antibody binding provides new insights into integrin conformational regulation. J Biol Chem. 2009 May 22;284(21):14337-46
PubMed
Schneider-Hohendorf T, Rossaint J, Mohan H, Böning D, Breuer J, Kuhlmann T, Gross CC, Flanagan K, Sorokin L, Vestweber D, Zarbock A, Schwab N, Wiendl H: VLA-4 blockade promotes differential routes into human CNS involving PSGL-1 rolling of T cells and MCAM-adhesion of TH17 cells. J Exp Med. 2014 Aug 25;211(9):1833-46.
PubMed
Yoon SO, Lee IY, Zhang X, Zapata MC, Choi YS: CD9 may contribute to the survival of human germinal center B cells by facilitating the interaction with follicular dendritic cells. FEBS Open Bio. 2014 Apr 13;4:370-6.
PubMed
Zhang XF, Feng MF: Adherence of human monocytes and NK cells to human TNF-alpha-stimulated porcine endothelial cells. Immunol Cell Biol. 2000 Dec;78(6):633-40.
PubMed
Soler D, Chapman T, Yang LL, Wyant T, Egan R, Fedyk ER: The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases. J Pharmacol Exp Ther. 2009 Sep;330(3):864-75.
PubMed
Variant
0.1 mg
11-171-C100
In stock

0.025 mg
11-171-C025
Out of stock
Variant
0.1 mg
11-261-C100
In stock

0.1 mg
11-261-C100
In stock